Ardelyx Inc (ARDX)

$5.31 -0.19 (-3.45%)
Market Cap 1.30B
Revenue (ttm) 407.32M
Net Income (ttm) -61.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.12%
Debt to Equity Ratio 1.21
Volume 8,465,200
Avg Vol 4,757,900
Day's Range N/A - N/A
Shares Out 245.25M
Stochastic %K 4%
Beta 0.61
Analysts Strong Sell
Price Target $16.10

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
ProgressiveDivision
ProgressiveDivision Mar. 22 at 5:11 AM
$ARDX biotech name, just observing calmly.
0 · Reply
SignalsCoreFlow
SignalsCoreFlow Mar. 22 at 5:08 AM
$ARDX biotech, just following along.
0 · Reply
tednitu
tednitu Mar. 21 at 11:12 PM
$ARDX on their web page Zydus claims they need to raise $600 mill. for their $2.2 - 2.5 bill. offer. if they don't do it now, when ardx is so low, when they plan to announce it ?
1 · Reply
Kevorolac
Kevorolac Mar. 21 at 8:44 PM
$ARDX Brought this up last year, but it now looks like there is now a US-based biotech with the license and DaVita funding.
0 · Reply
Kevorolac
Kevorolac Mar. 21 at 8:39 PM
$ARDX Phosphate transcellular absorption inhibitor AP306 is definitely something to be aware of. Likely will not be of major concern until 2030+ due to not starting Ph3 studies yet. Interesting science and could be a possible synergistic mechanism with tenapanor's paracellular absorption MOA. https://www.fiercebiotech.com/biotech/r1-zooms-out-stealth-775m-series-financing-advance-chronic-kidney-disease-treatment
0 · Reply
Cameohitch
Cameohitch Mar. 21 at 1:09 PM
$ARDX HR.2199 has changes in its summary. Haven't had time to check. It may be a meaningless comma... https://www.congress.gov/bill/119th-congress/house-bill/2199?loclr=cga-bill
0 · Reply
AndreTudisco
AndreTudisco Mar. 21 at 6:42 AM
$ARDX just came back for a sec to see what tards still think this is hitting$10 lmao
1 · Reply
lebranjames
lebranjames Mar. 21 at 1:16 AM
$ARDX forgetXPHOZAH, this is trading cheap even if it were just a 1 product company with IBSRELA. Market will have to change its tune eventually
0 · Reply
TheYoungGeologist
TheYoungGeologist Mar. 20 at 11:45 PM
$ARDX $MIST $HUMA enjoying the first fire at my new place tonight after the long Midwest winter, dreaming of my portfolio in 2 years...💸
2 · Reply
Alzemouse
Alzemouse Mar. 20 at 10:03 PM
$ARDX Some weekend lecture, for those who have not heard the Ways and Means hearing wednesday : https://waysandmeans.house.gov/2026/03/20/four-key-moments-hearing-on-improving-kidney-health-through-better-prevention-and-innovative-treatment/
3 · Reply
Latest News on ARDX
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar 12, 2026, 8:00 AM EDT - 9 days ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Mar 9, 2026, 4:05 PM EDT - 12 days ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Ardelyx to Participate in Upcoming Investor Conferences

Mar 4, 2026, 8:00 AM EST - 17 days ago

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Feb 24, 2026, 8:00 AM EST - 25 days ago

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Feb 21, 2026, 3:25 AM EST - 4 weeks ago

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Feb 20, 2026, 11:12 AM EST - 4 weeks ago

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Feb 20, 2026, 6:50 AM EST - 4 weeks ago

Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Feb 20, 2026, 2:44 AM EST - 4 weeks ago

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 19, 2026, 4:01 PM EST - 4 weeks ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Feb 5, 2026, 8:00 AM EST - 6 weeks ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Ardelyx Receives New Patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 6 weeks ago

Ardelyx Receives New Patent for Tenapanor

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Jan 28, 2026, 8:29 AM EST - 7 weeks ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Ardelyx: Assessment Of Acquisition Rumors

Jan 21, 2026, 1:04 PM EST - 2 months ago

Ardelyx: Assessment Of Acquisition Rumors

Ardelyx: IBSRELA Momentum Drives Opportunity

Jan 20, 2026, 6:14 AM EST - 2 months ago

Ardelyx: IBSRELA Momentum Drives Opportunity

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Jan 8, 2026, 8:30 AM EST - 2 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 7, 2025, 4:05 PM EST - 4 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 5, 2025, 8:00 AM EST - 4 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Nov 5, 2025, 4:24 AM EST - 4 months ago

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Ardelyx: A Long Overdue Rally

Nov 4, 2025, 3:32 PM EST - 4 months ago

Ardelyx: A Long Overdue Rally

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Nov 4, 2025, 8:00 AM EST - 4 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:06 PM EDT - 5 months ago

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 30, 2025, 4:01 PM EDT - 5 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 28, 2025, 8:01 AM EDT - 5 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:35 AM EDT - 5 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Oct 13, 2025, 8:30 AM EDT - 5 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:11 AM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 4:42 PM EDT - 7 months ago

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 15, 2025, 6:17 AM EDT - 7 months ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:11 PM EDT - 8 months ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 8 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:01 PM EDT - 8 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jul 21, 2025, 8:00 AM EDT - 8 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Jun 2, 2025, 4:05 PM EDT - 10 months ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 21, 2025, 8:00 AM EDT - 10 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 6, 2025, 8:01 AM EDT - 11 months ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

May 2, 2025, 10:07 AM EDT - 11 months ago

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:06 PM EDT - 11 months ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:01 PM EDT - 11 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 11 months ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ProgressiveDivision
ProgressiveDivision Mar. 22 at 5:11 AM
$ARDX biotech name, just observing calmly.
0 · Reply
SignalsCoreFlow
SignalsCoreFlow Mar. 22 at 5:08 AM
$ARDX biotech, just following along.
0 · Reply
tednitu
tednitu Mar. 21 at 11:12 PM
$ARDX on their web page Zydus claims they need to raise $600 mill. for their $2.2 - 2.5 bill. offer. if they don't do it now, when ardx is so low, when they plan to announce it ?
1 · Reply
Kevorolac
Kevorolac Mar. 21 at 8:44 PM
$ARDX Brought this up last year, but it now looks like there is now a US-based biotech with the license and DaVita funding.
0 · Reply
Kevorolac
Kevorolac Mar. 21 at 8:39 PM
$ARDX Phosphate transcellular absorption inhibitor AP306 is definitely something to be aware of. Likely will not be of major concern until 2030+ due to not starting Ph3 studies yet. Interesting science and could be a possible synergistic mechanism with tenapanor's paracellular absorption MOA. https://www.fiercebiotech.com/biotech/r1-zooms-out-stealth-775m-series-financing-advance-chronic-kidney-disease-treatment
0 · Reply
Cameohitch
Cameohitch Mar. 21 at 1:09 PM
$ARDX HR.2199 has changes in its summary. Haven't had time to check. It may be a meaningless comma... https://www.congress.gov/bill/119th-congress/house-bill/2199?loclr=cga-bill
0 · Reply
AndreTudisco
AndreTudisco Mar. 21 at 6:42 AM
$ARDX just came back for a sec to see what tards still think this is hitting$10 lmao
1 · Reply
lebranjames
lebranjames Mar. 21 at 1:16 AM
$ARDX forgetXPHOZAH, this is trading cheap even if it were just a 1 product company with IBSRELA. Market will have to change its tune eventually
0 · Reply
TheYoungGeologist
TheYoungGeologist Mar. 20 at 11:45 PM
$ARDX $MIST $HUMA enjoying the first fire at my new place tonight after the long Midwest winter, dreaming of my portfolio in 2 years...💸
2 · Reply
Alzemouse
Alzemouse Mar. 20 at 10:03 PM
$ARDX Some weekend lecture, for those who have not heard the Ways and Means hearing wednesday : https://waysandmeans.house.gov/2026/03/20/four-key-moments-hearing-on-improving-kidney-health-through-better-prevention-and-innovative-treatment/
3 · Reply
sunnysky10
sunnysky10 Mar. 20 at 9:22 PM
$ARDX What a lousy week for us! Hopefully we will go up now that OPEX is over for this month!
0 · Reply
opportoni
opportoni Mar. 20 at 8:20 PM
$ARDX I hate to say it, but most likely we will now close the gap at $5.01. Another one looming at $4.44. Hope we don’t go there.
4 · Reply
MedHS55
MedHS55 Mar. 20 at 8:03 PM
$ARDX Huge MOC and related trades
1 · Reply
FerreroRocher
FerreroRocher Mar. 20 at 8:00 PM
$ARDX Is it Monday yet?
1 · Reply
Memphis75
Memphis75 Mar. 20 at 7:59 PM
$ARDX Just curious, what happened to Tony?
1 · Reply
GladysFoster
GladysFoster Mar. 20 at 7:52 PM
$ARDX close market damn you, close....
0 · Reply
MedHS55
MedHS55 Mar. 20 at 7:49 PM
$ARDX color me not surprised
1 · Reply
ToadTrader
ToadTrader Mar. 20 at 7:49 PM
$ARDX You all take care! Have a great weekend... hoping for a better directional move in the coming weeks! CHEERS!
1 · Reply
Burning_Cash
Burning_Cash Mar. 20 at 7:20 PM
$ARDX
0 · Reply
BabaBooey2020
BabaBooey2020 Mar. 20 at 7:06 PM
$ARDX 🤬
0 · Reply
GladysFoster
GladysFoster Mar. 20 at 6:36 PM
$ARDX
2 · Reply
KevinDL
KevinDL Mar. 20 at 6:32 PM
$ARDX 500 more at $5.37. I may be loosing my mind… and my ass.
0 · Reply